Share on LinkedInShare on LinkedIn

ARTICLE · 31 MARCH 2017

Tribunal Decides In Favour Of Canada In NAFTA Arbitration Suit

Eli Lilly and Company sued the government as a result of the invalidation, by Canadian courts, of the patents that protected Lilly's drugs Strattera® and Zyprexa®.

CanadaIntellectual Property

The Government of Canada has prevailed in its NAFTA arbitration suit with Eli Lilly and Company ["Lilly"]. Lilly sued the government as a result of the invalidation, by Canadian courts, of the patents that protected Lilly's drugs Strattera® and Zyprexa®. The patents were invalidated on the basis they lacked utility after application of the promise doctrine. The promise doctrine involves a review of the specification of a patent to determine whether the inventors have made a promise concerning the invention's utility. If a court finds that the inventors made a promise, whether explicitly or implicitly, the patent will only have utility if that promise is fulfilled. As such, the promise doctrine can increase the threshold required for a finding of utility. Lilly's patents covering their drugs were invalidated as a result of the application of the promise doctrine.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from